Collegium To Participate In 2026 Jefferies Global Healthcare Conference
Details of the event are as follows:
Fireside Chat Date and Time: Wednesday, June 3, 2026, at 1:20 p.m. ET
New York, NY
A live webcast of the fireside chat will be available via the Investors section of the Company's website: . A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. Collegium has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions.
With a portfolio of differentiated ADHD medications, anchored by JORNAY PM® (methylphenidate HCl) and AZSTARYS® (serdexmethylphenidate and dexmethylphenidate), and an established leadership position in responsible pain management, Collegium leads with the scientific rigor and commercial expertise to deliver treatment options around how people live their lives. For more information, please visit collegiumpharma or find us on LinkedIn.
Investor Contact:
Ian Karp
Head of Investor Relations
...
Media Contact:
Jessica Cotrone
Senior Vice President, Corporate Communications & Corporate Affairs
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment